8th Translational Research Conference
Lymphoid Malignancies
Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt, Catherine Wu

8th Translational Research Conference
Lymphoid Malignancies
ABOUT THE CONFERENCE:
This leading-edge translational research conference will address the rapidly evolving field of lymphoid malignancies, including T- and B-cell lymphomas, and chronic lymphocytic leukaemia (CLL), from molecular pathogenesis to state-of-the-art treatment and future perspectives.
The goals of this conference are to:
– Foster scientific exchange between laboratory scientists and clinicians working on lymphoid malignancies worldwide.
– Foster scientific cross-fertilization between researchers and clinicians working on different diseases with partially overlapping pathogenic mechanisms such as the B cell receptor signaling, alterations of the DNA damage response, or the increasingly important dialogue of lymphoid tumour cells with their microenvironment.
– Provide opportunities for leading-edge education and international networking to basic and clinical scientists, including those still in-training.
A first-class selection of international speakers will guarantee the highest quality of science and a summary of the most recent developments in the biology and therapy of Lymphoid Malignancies.
This educational conference has been approved for 20 CME-CPD credit points by the European Board for Accreditation in Haematology (EBAH)!
SCIENTIFIC TOPICS:
• Biology of lymphoma
• Clonal evolution
• Lymphoma cell interactions in the tumor microenvironment
• Monoclonal antibodies & non-cellular immune therapies
• Cellular immune therapies • Small molecular pathway inhibitors
• Development of novel treatment paradigms
• Novel Bio markers for diagnostic and therapeutic monitoring
Programme
Read the final programme!
Corporate partners
With the support of*:

Emerald Conference Partners
*******



Ruby Conference Partners
*******
*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.